News | 30 May 2023
Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
The PP-based top and bottom webs are manufactured in a unique coextrusion process
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Product deliveries scheduled in Q3 of 2023
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
Continues to Expand its Presence in South India
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
